A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

MLA

Laubach, Jacob P., et al. “A Retrospective Analysis of 3954 Patients in Phase 2/3 Trials of Bortezomib for the Treatment of Multiple Myeloma: Towards Providing a Benchmark for the Cardiac Safety Profile of Proteasome Inhibition in Multiple Myeloma.” British Journal of Haematology, vol. 178, no. 4, Aug. 2017, pp. 547–60. EBSCOhost, https://doi.org/10.1111/bjh.14708.

APA

Laubach, J. P., Moslehi, J. J., Francis, S. A., San Miguel, J. F., Sonneveld, P., Orlowski, R. Z., Moreau, P., Rosiñol, L., Faber, E. A., Voorhees, P., Mateos, M. ‐ V., Marquez, L., Feng, H., Desai, A., Velde, H., Elliott, J., Shi, H., Dow, E., Jobanputra, N., & Esseltine, D. ‐ L. (2017). A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 178(4), 547–560. https://doi.org/10.1111/bjh.14708

Chicago

Laubach, Jacob P., Javid J. Moslehi, Sanjeev A. Francis, Jesús F. San Miguel, Pieter Sonneveld, Robert Z. Orlowski, Philippe Moreau, et al. 2017. “A Retrospective Analysis of 3954 Patients in Phase 2/3 Trials of Bortezomib for the Treatment of Multiple Myeloma: Towards Providing a Benchmark for the Cardiac Safety Profile of Proteasome Inhibition in Multiple Myeloma.” British Journal of Haematology 178 (4): 547–60. doi:10.1111/bjh.14708.